This week at HLTH, FDA Commissioner Robert Califf discussed the current state of healthcare AI. He talked about some of the qualms he has, such as his worry that AI is worsening health inequities and his concern that providers aren't capable of validating AI tools' effectiveness.
Radiant Biotherapeutics' Multabodies are antibodies engineered to offer better binding strength to their targets. The preclinical startup's lead program goes after a cancer immunotherapy target being pursued by several biotech companies already in early clinical development.
Sach Jain, the CEO of Carrum Health, which helps self-insured employers manage their surgical care costs, had a sobering perspective at HLTH, a conference that celebrates innovation in healthcare.
Despite the challenges of interoperability, regulatory compliance, technology adoption, and data privacy, the benefits of digital health are undeniable. Collaboration between policymakers, clinicians, IT developers, and patients, can help overcome these obstacles.
As the field of oncology evolves, we need to shift away from traditional binary "yes-no" biomarkers to a more nuanced, spatial understanding of tumor biology. This approach will allow for more personalized treatment plans that are tailored to the unique characteristics of each patient's tumor.
In this episode, we talk about virtual care and how Dr. Eve Cunningham approaches technology to scale remote care programs to help physicians managing chronic disease patients. We also address how the Federal Trade Commission is suing the three largest pharmacy benefit managers for their role in keeping insulin prices high when lower priced insulin was already available.
No comments